Results 71 to 80 of about 8,510 (199)

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan

Cancer Science, EarlyView.
The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada, Akiko M. Saito, Kei Fukuhara, Masahiro Sekimizu   +12 more
wiley   +1 more source

Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer

Journal of the Formosan Medical Association
Background: Lorlatinib is a brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) inhibitor indicated for ALK-positive metastatic non-small cell lung cancer (NSCLC).
Jin-Yuan Shih, Yung-Hung Luo, Gee-Chen Chang, John Wen-Cheng Chang, Chin-Chou Wang, Tsung-Ying Yang, Wei-Tse Fang, Wen-Yi Shau   +7 more
doaj   +1 more source

Acute worsening of glycemic control in a patient with type 2 diabetes and non‐small cell lung cancer after administration of lorlatinib

Clinical Case Reports, 2022
A patient with non‐small cell lung cancer (NSCLC) exhibited extreme hyperglycemia after lorlatinib treatment. The present case highlights the importance of glucose monitoring during lorlatinib administration and intensifying hyperglycemia treatment.
Yoshio Nakano, Mai Miyasato‐Isoda, Iwao Gohma, Tomomi Fujisawa   +3 more
doaj   +1 more source

Efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer patients with progression on crizotinib: personal experience

Медицинский совет, 2021
Introduction. Lorlatinib is a  third generation ALK tyrosine kinase inhibitor. Back in  2018, the  drug underwent accelerated FDA approval and was recommended for the treatment of patients with ALK-positive non-small cell lung cancer after progression on
K. K. Laktionov, E. V. Reutova, S. Yu. Kruteleva, E. Yu. Antonova   +3 more
doaj   +1 more source

A Patient‐Derived Organoid Biobank of Adamantinomatous Craniopharyngioma as a Platform for Drug Discovery

Advanced Science, Volume 13, Issue 7, 3 February 2026.
This study successfully establishes adamantinomatous craniopharyngioma (ACP) patient‐derived organoids (PDOs) that preserve the histopathological and genetic features of the original tumors. Through drug sensitivity assays and subsequent mechanistic analyses, the study demonstrates that Ceritinib exerts its inhibitory effects on ACP PDO growth by ...
Huarong Zhang, Chaohu Wang, Jun Fan, Zexin Chen, Haoying Yu, Yawen Bai, Tingcheng Zhang, Qianchao Zhu, Yiwen Feng, Peirong Niu, Jiaqian Chen, Liping Yang, Xueying Li, Lei Yu, Songtao Qi, Yi Liu   +15 more
wiley   +1 more source

Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system

Frontiers in Pharmacology
BackgroundLorlatinib displays marked systemic and intracranial efficacy against anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). We aimed to establish the safety profile of lorlatinib based on the Food and Drug Administration
Huqun Li, Chongshu Wang, Cuilian Guo
doaj   +1 more source

Efficacy and safety of first-line treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a Bayesian network meta-analysis. [PDF]

, 2021
Background: Targeted therapies have led to significant improvement in the management and prognosis of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). We performed a network meta-analysis of frontline treatment options of ALK-
Hong, S, Liang, F, Lu, D, Peng, L, Selvaggi, G, Stebbing, J, Sun, Y, Xia, Y   +7 more
core   +2 more sources

Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non‐Small Cell Lung Cancer With ROS1 Rearrangement

Cancer Medicine, Volume 15, Issue 2, February 2026.
Survival outcomes in gradual/local progression group were superior to dramatic progression group; survival period of dramatic progression group who received chemotherapy was longer than that of other therapies. ROS1 kinase domain mutations were detected predominantly in dramatic progression group, whereas activation of bypass and downstream pathways ...
Quan‐Quan Tan, Yu‐Qing Chen, Yu‐Er Gao, Ke‐Jun Liu, Zi‐Ji Mao, Ming‐Ying Zheng, Jun‐Wei Su, Jiao Yang, Qing‐Yun Gao, Hua‐Jun Chen, Jin‐Ji Yang   +10 more
wiley   +1 more source

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

Nature Communications, 2021
Resistance to ALK inhibitors such as lorlatinib often arise due to on-target mutations. Here, the authors show the multi-kinase inhibitor gilteritinib is effective against different mutations that arise during lorlatinib in ALK fusion positive lung ...
Hayato Mizuta, Koutaroh Okada, Mitsugu Araki, Jun Adachi, Ai Takemoto, Justyna Kutkowska, Kohei Maruyama, Noriko Yanagitani, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Luc Friboulet, Kazuhiro Katayama, Biao Ma, Yoko Sasakura, Yukari Sagae, Mutsuko Kukimoto-Niino, Mikako Shirouzu, Satoshi Takagi, Siro Simizu, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama   +23 more
doaj   +1 more source

Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib

Frontiers in Oncology, 2023
IntroductionInfant type hemispheric gliomas are a rare tumor with unique molecular characteristics. In many cases these harbor mutations in receptor tyrosine kinase pathways and respond to targeted therapy.
Shubin W. Shahab, Shubin W. Shahab, Matthew Schniederjan, Matthew Schniederjan, Jose Velazquez Vega, Jose Velazquez Vega, Stephen Little, Andrew Reisner, Andrew Reisner, Andrew Reisner, Tobey MacDonald, Tobey MacDonald, Tobey MacDonald, Dolly Aguilera, Dolly Aguilera   +14 more
doaj   +1 more source